Longevity & Biotech Pre-IPO

Early-stage investments in the health-span economy — anti-aging, biotech, and longevity tech.

Market Size
$25B longevity sector (2024), projected $600B by 2035; $1.5T global biotech industry
Typical Returns
Biotech stocks: -80% to +500% (binary clinical outcomes); Biotech ETFs: -20% to +60% annually; VC funds: 15-30% IRR (top quartile)

5 tracked longevity and biotech offerings →

Largest SEC filers in longevity biotech

Ranked by the total reported sold on the latest Form D or Regulation A notice. Each page carries the filing record, the related persons and what to check; AltStreet gives no verdict on an issuer.

Overview

Longevity and biotech investing targets therapies extending healthspan and lifespan—anti-aging drugs, gene therapies, senolytics, metabolic health, regenerative medicine. Market size: $25B+ longevity sector (2024), projected $600B by 2035. Investment access: (1) Public biotech stocks (Geron, Unity Biotechnology), (2) Biotech ETFs (XBI, IBB, ARKG), (3) VC funds (Longevity Fund, Apollo Health Ventures), (4) Crowdfunding (Republic, StartEngine). Returns highly binary: 90% fail but successes deliver 10-100x (Moderna, BioNTech). Risks: 70% Phase III failure rate, regulatory delays, capital intensity. Suitable for 10+ year horizons and high volatility tolerance.

Key Benefits

  • Exponential growth potential: Longevity market projected 24x growth (2024-2035); comparable to internet in 1995
  • Demographic tailwinds: Global 65+ population reaches 1.5B by 2050; aging drives healthspan demand
  • Platform technologies: CRISPR, mRNA, AI drug discovery enable faster development and lower costs
  • Regulatory fast-tracking: FDA Breakthrough Therapy designation; COVID proved regulatory flexibility
  • Diversification: Biotech 0.2-0.4 correlation with S&P 500; clinical results uncorrelated with macro
  • Patent protections: 20-year exclusivity creates moats; successful drugs generate $1B-$10B+ revenue
  • Asymmetric returns: Limited downside (stock → $0) but unlimited upside (10-100x on approvals)

Platform Reviews

In-depth analysis using our three-pillar evaluation framework

View All

BioTech Funding Portal

Biotech / Early-Stage Life Science EquityRegulation Crowdfunding Portal (Life Sciences)

BioTech Funding Portal (biotech.fund) is a Regulation Crowdfunding portal only for life-science companies, open to accredited and non-accredited investors with minimums from $500. It filed its funding portal registration in November 2024 and announced its public launch on June 22, 2026; as of November 9, 2026 no company has filed an offering through it. Its offerings page lists two drug developers Testing the Waters, each proposing a $1 million raise on a SAFE: Glafabra Therapeutics (Fabry disease; $12 million cap, 20% discount, $1,000 minimum) and Energesis Pharmaceuticals (obesity; CrowdSAFE, $500 minimum). The terms are preliminary and the listings accept only expressions of interest. A fictional demo company sits beside them. Investors pay no portal fee; issuers' fees will appear in each Form C.

Updated Nov 10, 2026

Capital Cell

Biotech / Early-Stage Life Science EquityEU Equity Crowdfunding Platform (Life Sciences)

Capital Cell is a Barcelona equity crowdfunding platform for early-stage biotech and medical companies, licensed by Spain's CNMV under the EU crowdfunding regulation and open across 26 other EU states from about EUR 500 a ticket. Its public track record lists 156 rounds since April 2016 (EUR 157.1 million of round size, including lead investors): 138 'In business', 14 'Write-off' and 4 'Exit' at three companies, with exit proceeds not published. Its own analysis of the 2015 to 2022 portfolio put reported value at 3.19x invested capital on paper, 1.14x without its three best investments, and cash returned as of November 2022 at 0.51.

Updated Nov 10, 2026

VitaDAO

Governance token of a longevity-research funding collective; IP tokens in individual research projectsDecentralized Science (DeSci) DAO with a Tradable Governance Token and IP Tokens

VitaDAO is a decentralized autonomous organization that funds early-stage longevity research and holds the resulting equity stakes and intellectual property. Anyone can buy its VITA governance token, which carries votes on funding and the treasury; AltStreet located no contractual or published right giving holders a claim on the DAO's assets or income. VITA traded at $0.265 on October 5, 2026, down 83% in a year and 96% below its January 2025 high. One VitaDAO-associated Ethereum Safe that AltStreet priced held about $3.7 million, mostly VITA and related ecosystem and project tokens, some of which barely trade; this is not a consolidated valuation of VitaDAO's treasury. Formal Snapshot voting has fallen to five proposals in 2025 and none in 2026, though forum discussion and a monthly newsletter continue.

Updated Oct 5, 2026

Investing in Longevity & Biotech

1

Start with Diversified Biotech ETF

SPDR S&P Biotech ETF (XBI) holds 100+ biotech stocks equally weighted; reduces single-stock risk. Expense ratio 0.35%. Alternative: ARK Genomic Revolution (ARKG) focuses on gene editing, CRISPR, AI drug discovery. Allocate 5-10% of portfolio.

2

Identify Clinical Trial Catalysts

Track clinicaltrials.gov for Phase II/III readouts. Phase II success = 30-50% stock pop; Phase III success = 100-300% pop; failures = -60-80% crash. Invest pre-readout for maximum upside but accept binary risk.

3

Focus on Platform Technologies

Companies with platforms (CRISPR, mRNA, AI) can pivot to multiple indications if one fails. Examples: Intellia (CRISPR), Moderna (mRNA), Recursion (AI). Platforms reduce binary risk vs. single-asset biotechs.

4

Consider Crowdfunding for Early-Stage

Republic, StartEngine offer equity crowdfunding in longevity startups. Minimums $100-$1K. Extremely risky: 90% fail, but winners deliver 10-50x. Allocate <1-2% of portfolio; lottery tickets with upside optionality.

Longevity & Biotech Risks

Important considerations before investing in longevity & biotech pre-ipo

  • Clinical trial failure: 70% of drugs fail Phase III; single negative readout drops stock 60-80% in one day
  • Capital intensity: Drug development costs $500M-$2B+ over 10-15 years; frequent dilutive raises (30-50% dilution)
  • Regulatory risk: FDA rejection or delays add years; unexpected safety issues kill drugs
  • Patent cliffs: Exclusivity expires after 20 years; generics enter, revenue drops 80-90%
  • Binary outcomes: Stocks move on single catalysts; difficult to predict with fundamental analysis
  • Market timing: Biotech highly cyclical; crashes 40-60% in bear markets (2022: XBI -40%)
  • Small-cap liquidity: Many biotech stocks trade <$100K daily; 10-20% bid-ask spreads
  • Science risk: Early-stage mechanisms unproven; what works in mice often fails in humans (90% attrition)

Due Diligence Checklist

  • Track clinical trial calendar: Use clinicaltrials.gov for Phase II/III readouts; invest 3-6 months before catalysts
  • Assess cash runway: Divide cash by quarterly burn; need 18-24 months runway (<12 months = red flag)
  • Evaluate mechanism of action: Understand drug biological mechanism; novel = riskier but higher upside
  • Check Key Opinion Leader sentiment: Twitter, conferences, research notes reveal expert opinions on success likelihood
  • Review trial design: Endpoint (survival vs. surrogate), patient population, statistical power; poor design = higher failure
  • Understand regulatory pathway: Breakthrough Therapy (accelerated) vs. standard? Accelerated = 2-3 years faster
  • Assess competition: How many competitors in same indication? Crowded spaces face partnership/pricing pressure
  • Diversify across 10-20 biotech stocks: Single stock = lottery ticket; portfolio captures winners, limits failures

Real-World Examples

Moderna (MRNA): IPO $23 (2018), peaked $450 (2021) on COVID vaccine = 19x return in 3 years. Now $100 (2024) post-COVID.

Unity Biotechnology (UBX): IPO $16 (2018), peaked $21 (2020), crashed to $1 (2024) after Phase II failure. -94% loss. Binary risk.

Intellia (NTLA): IPO $20 (2019), peaked $180 (2021) on positive Phase I, corrected to $20 (2024). Awaiting Phase III readout.

XBI ETF (2010-2024): $10K grew to $35K (9.2% CAGR). Outperformed S&P 500 in some periods, underperformed others. High volatility.

BioNTech (BNTX): Pre-COVID $20 (2019), peaked $400 (2021) = 20x. Illustrates platform value (mRNA pivoted cancer to vaccines).

Longevity & Biotech Pre-IPO: frequently asked questions

How do you invest in longevity and biotech?

Public routes include biotech ETFs, such as the SPDR S&P Biotech ETF (XBI), which held 165 stocks on an equal-weighted basis at October 23, 2026, and individual drug developers working on aging-related diseases. Most companies explicitly focused on longevity are private, so access otherwise comes through venture funds, angel networks and crowdfunding portals.

Source: State Street SPDR XBI fund page

Who is funding longevity startups?

Mostly large venture funds and technology founders. NewLimit, co-founded by Coinbase's Brian Armstrong, raised a $435 million Series C led by Founders Fund in June 2026, according to STAT. Rounds like these are not open to individual investors.

Source: STAT, June 2, 2026

Can non-accredited investors invest in biotech startups?

Yes, through Regulation Crowdfunding portals, within annual limits. Investors whose income or net worth is under $124,000 can invest the greater of $2,500 or 5% of the greater of the two across all Reg CF offerings in 12 months; others can invest 10%, up to $124,000. Companies can raise at most $5 million a year this way. Accredited investors, defined by $1 million net worth excluding the home or $200,000 income ($300,000 joint), have no such limits.

Sources: SEC, Regulation Crowdfunding; SEC, accredited investors

Why is biotech investing so risky?

Most drug candidates fail in clinical trials, development takes a decade or more, and young companies usually need to raise money repeatedly, diluting earlier investors. Longevity therapies face an extra hurdle: regulators approve drugs for diseases, not for aging itself, so companies must prove benefit against a specific condition.

Biotech and longevity reference library

Royalty and financing mechanics behind biotech and longevity investments. 3 terms.

All terms: AltStreet reference index and glossary.